Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as an Elite provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is currently accepting new patients.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference. Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty. As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation. Dr. Sterling is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

Dr. Rima Jean Couzi is a cancer specialist in Towson, Maryland, caring for patients with breast cancer. Dr. Couzi earned her medical degree at the National University of Ireland. She completed residencies at St. Laurence's Hospital/Beaumont Hospitals and Galway Regional in Dublin, as well as Franklin Square Hospital in Baltimore. She performed a fellowship in medical oncology at St. Vincent's Hospital and St. James's Hospital in Dublin, and an additional fellowship in medical oncology at Johns Hopkins Oncology Center in Baltimore. She also earned a master’s degree in clinical epidemiology from the Johns Hopkins Bloomberg School of Public Health. Dr. Couzi joined the Johns Hopkins faculty in 2004. Dr. Couzi is a member of the American Society of Clinical Oncology and the Royal College of Physicians in Ireland. Selected Publications Antonarakis ES, Fradin JM, Petronis JD, Couzi RJ. “Not What It Seems.” Am J Med. 2007;120:408-411 Holdhoff M, Wung PK, Petronis J, Couzi R. “Persistent PET-positive liver lesions after successful chemotherapy in a patient with mediastinal seminoma.” J. Clin Oncol. 2007;25:2482-4. Li S, Couzi RJ, Thomas GH, Friedman AD, Borowitz MJ. “A novel variant three-way translocation of inversion 16 in a case of AML-M4eo following low dose methotrexate therapy.” Cancer Genet Cytogenet. 2001; 125:74-7. Schultz MJ, Tabb RD, Eagan JW, Citron JR, Couzi RJ. “Treating a male breast cancer patient with moderately differentiated, infiltrating ductal cancer of the breast.” Journal of Multidisciplinary Cancer Care. 2009 September – October. Siegelbaum MH, Citron JR, Eagan JW, Couzi RJ. “Treating a patient with Unfavorable-risk prostate cancer.” Journal of Multidisciplinary Cancer Care. 2009; July – August. Dr. Couzi is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Robert Donegan is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Donegan is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Non-Hodgkin Lymphoma, and Angiosarcoma. Dr. Donegan is currently accepting new patients.

Maitri Kalra is a Hematologist Oncology specialist and an Oncologist in Lutherville, Maryland. Dr. Kalra has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Judy Hetherington is a Nurse Practitioner in Lutherville, Maryland. Ms. Hetherington is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. Her top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Breast Cancer, and Paget Disease of the Breast.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Gang Chen is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Colorectal Cancer, Myelodysplastic Syndrome (MDS), Familial Colorectal Cancer, Paget Disease of the Breast, and Hepato-Pancreato-Biliary Surgery. Dr. Chen is currently accepting new patients.

Richard Schraeder is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Schraeder is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

Eric Seifter is a Hematologist Oncology specialist and a Hematologist in Lutherville, Maryland. Dr. Seifter is rated as an Advanced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome.

Christopher Melani is a primary care provider, practicing in Internal Medicine in Baltimore, Maryland. Dr. Melani is rated as a Distinguished provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Lymphomatoid Granulomatosis, Primary Mediastinal B-Cell Lymphoma (PMBCL), B-Cell Lymphoma, and Non-Hodgkin Lymphoma.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer.

I am a physician-scientist in the Division of Hematological Malignancies and stem cell transplantation at the Sidney Kimmel Comprehensive Cancer Center, where I specialize in the treatment of lymphomas. My primary research focuses on developing new biologic therapies for the treatment of T-cell lymphomas and T-cell leukemias. Dr. Paul is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and T-Cell Lymphoma.

Laura Wake, M.D., is a hematopathologist at the Johns Hopkins Hospital, and an Assistant Professor in the Department of Pathology at the Johns Hopkins University School of Medicine. Dr. Wake's pathology expertise extends to hematology and oncology. She specifically focuses on hematologic cancers and lymphoid malignancies. Dr. Wake earned her medical degree at the American University of the Caribbean School of Medicine. She completed an anatomic and clinical pathology residency at the University of Nebraska Medical Center and a hematopathology fellowship at the National Institutes of Health/National Cancer Institute. Dr. Wake is the Medical Director of the Johns Hopkins Hospital Flow Cytometry Laboratory and is the Program Director of the Hematopathology Fellowship at Johns Hopkins. Dr. Wake has contributed to numerous publications on hematopathology research. Dr. Wake is rated as an Experienced provider by MediFind in the treatment of Non-Hodgkin Lymphoma. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Acute Myeloblastic Leukemia with Maturation.